Chinese and Swiss researchers have published ‘Mass spectrometry-based proteomic quest for diabetes biomarkers’ in ‘Biochimica et Biophysica Acta’ an internationally recognized scientific journal suggesting that pressure cycling technology (or PCT) being developed by Pressure BioSciences could be critical in identifying new biomarkers for the early diagnosis progression and underlying pathway dysfunction of diabetes. As such they could also significantly improve the clinical management of this disorder. In the article the authors which included Dr. Shiying Shao of the Tongji Hospital Huazhong University of Science and Technology (Wuhan PR China) and Drs. Tiannan Guo and Ruedi Aebersold of the Institute of Molecular Systems Biology ETH Zurich (Zurich Switzerland) reviewed the current status of biomarker discovery in diabetes showing the need for limitations and possible solutions for biomarker discovery and validation in the field of diabetes research.